Collegium Pharmaceutical
COLL
128 hedge funds and large institutions have $406M invested in Collegium Pharmaceutical in 2019 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 53 increasing their positions, 33 reducing their positions, and 37 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 33
57% more call options, than puts
Call options by funds: $1.16M | Put options by funds: $735K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.94% less ownership
Funds ownership: 94.31% → 92.37% (-1.9%)
12% less funds holding
Funds holding: 145 → 128 (-17)
15% less capital invested
Capital invested by funds: $476M → $406M (-$71M)
38% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$9.28M |
| 2 |
Renaissance Technologies
New York
|
+$3.26M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$3.22M |
| 4 |
CAM
Cortina Asset Management
Milwaukee,
Wisconsin
|
+$3.05M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$25.6M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
-$5.98M |
| 3 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$3.57M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.03M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$2.67M |
COLL Hedge Fund Activity: Q2 2019 in Review
128 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q2 2019, worth a combined $406M — down 15% from $476M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of COLL and 23 opened new positions — a net loss of 14 holders — while 33 trimmed existing stakes and 53 added.
The largest buyer was Janus Henderson Group, adding an estimated $9.28M. The largest seller was Macquarie Group, cutting an estimated $25.6M.
- 128 institutional investors held Collegium Pharmaceutical (COLL) as of Q2 2019, down from 145 in Q1 2019.
- Funds reported $406M of Collegium Pharmaceutical stock for Q2 2019, down 15% quarter-over-quarter.
- 23 funds opened new Collegium Pharmaceutical positions in Q2 2019 and 37 closed out, a net change of -14 holders.
- The largest Collegium Pharmaceutical buyer in Q2 2019 was Janus Henderson Group, an estimated $9.28M added.
- The largest Collegium Pharmaceutical seller in Q2 2019 was Macquarie Group, an estimated $25.6M sold.
Based on aggregated 13F filings for Q2 2019.